[go: up one dir, main page]

MX2010003660A - Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo. - Google Patents

Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.

Info

Publication number
MX2010003660A
MX2010003660A MX2010003660A MX2010003660A MX2010003660A MX 2010003660 A MX2010003660 A MX 2010003660A MX 2010003660 A MX2010003660 A MX 2010003660A MX 2010003660 A MX2010003660 A MX 2010003660A MX 2010003660 A MX2010003660 A MX 2010003660A
Authority
MX
Mexico
Prior art keywords
skin
remedy
active ingredient
acid addition
addition salt
Prior art date
Application number
MX2010003660A
Other languages
English (en)
Inventor
Shinji Ona
Koichiro Takeshita
Naoki Ando
Masahiro Yamashita
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2010003660A publication Critical patent/MX2010003660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

El objeto de esta invención es proporcionar una medicina novedosa útil para terapia para mejorar las propiedades de la piel tales como secado de la piel, endurecimiento de la piel y el oscurecimiento de la piel involucrado en hiperqueratinosis ( capa de queratina engrosada ) mediante un efecto de retención de humedad de piel contra el declive de las funciones de la piel traídas por varias causas. Esta invención proporciona un agente terapéutico de mejoramiento de propiedades de la piel que comprende un compuesto teniendo un esqueleto de morfinano específico tipificado por un compuesto 1 representado por la siguiente fórmula (II) o cualquiera de sus sales de adición de ácido farmacológicamente permisibles como un ingrediente activo.
MX2010003660A 2007-10-05 2008-10-03 Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo. MX2010003660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007262015 2007-10-05
PCT/JP2008/068092 WO2009044883A1 (ja) 2007-10-05 2008-10-03 モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬

Publications (1)

Publication Number Publication Date
MX2010003660A true MX2010003660A (es) 2010-08-10

Family

ID=40526303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003660A MX2010003660A (es) 2007-10-05 2008-10-03 Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.

Country Status (14)

Country Link
US (1) US20100222309A1 (es)
EP (1) EP2196206B8 (es)
JP (1) JP5613417B2 (es)
KR (1) KR101173509B1 (es)
CN (1) CN101848714B (es)
AU (1) AU2008308005B2 (es)
BR (1) BRPI0817804A8 (es)
CA (1) CA2702032C (es)
ES (1) ES2748274T3 (es)
MX (1) MX2010003660A (es)
PL (1) PL2196206T3 (es)
RU (1) RU2440117C1 (es)
TW (1) TWI453020B (es)
WO (1) WO2009044883A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10131672B2 (en) * 2010-01-29 2018-11-20 Toray Industries, Inc. Therapeutic or prophylactic agent for biliary diseases
JP6013345B2 (ja) 2010-10-19 2016-10-25 メモリアル スローン−ケタリング キャンサー センター 痛み治療用の４，５ａ−エポキシモルフィナンの６−アミド誘導体
EP2671585B1 (en) 2011-01-31 2016-07-13 Toray Industries, Inc. (-)-17-(cyclopropylmethyl)-3,14ß-dihydroxy-4,5a-epoxy-6ß-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan for use in treating or preventing cancer cachexia
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
EP2941431B1 (en) 2012-12-28 2017-10-25 Purdue Pharma L.P. Substituted morphinans and the use thereof
CA2983314C (en) 2015-04-30 2024-11-12 Memorial Sloan-Kettering Cancer Center Mitragynine analogues and their uses
CN105461727A (zh) * 2015-12-01 2016-04-06 吕涛 一种纳呋拉啡的精制方法
WO2018160500A1 (en) 2017-03-03 2018-09-07 Ring Inc. Solar-charging mounting bracket for audio/video recording and communication devices
US20210015813A1 (en) 2018-03-08 2021-01-21 Victoria Link Ltd. Treatment of demyelinating diseases
KR20230031207A (ko) * 2020-06-30 2023-03-07 도레이 카부시키가이샤 대사이상을 수반하는 질환 또는 증후군에 있어서의 근력 저하 증상의 개선제 또는 예방제
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923875A (en) * 1989-07-10 1990-05-08 Baker Cummins Pharmaceuticals, Inc. Method for treatment of mast cell-mediated dermatologic disorders
JP2521853B2 (ja) 1990-07-25 1996-08-07 タカラベルモント株式会社 化粧料
DK0577847T3 (da) 1992-01-23 1999-06-23 Toray Industries Morphinanderivat og medicinsk anvendelse deraf
DE69414085T2 (de) 1993-07-19 1999-03-18 Toray Industries, Inc., Tokio/Tokyo Wirkstoff zum schutze von gehirnzellen
CA2143864C (en) * 1993-07-23 2006-01-24 Hiroshi Nagase Morphinan derivatives and pharmaceutical use thereof
JPH07187990A (ja) 1993-12-24 1995-07-25 Toshiko Yamamoto 化粧料
ES2215158T3 (es) 1996-11-25 2004-10-01 Toray Industries, Inc. Agente antipruritico.
US5834480A (en) * 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
AU6117298A (en) 1997-07-25 1999-02-16 Toray Industries, Inc. Hyponatremia remedies
JP4359711B2 (ja) 1997-09-02 2009-11-04 東レ株式会社 薬物依存症治療薬
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
ES2308990T3 (es) 1999-08-24 2008-12-16 Toray Industries, Inc. Remedios para el dolor neuropatico y modelos animales de dolor neuropatico.
PT1380306E (pt) 2001-03-30 2009-05-25 Toray Industries Medicamentos para psiconeurose
EP1402899A4 (en) 2001-05-08 2009-03-11 Toray Industries MEANS FOR THE TREATMENT OF SEPSIS
JP2004107209A (ja) 2002-09-13 2004-04-08 Nippon Oruganon Kk 掻痒治療薬
RU2221545C1 (ru) * 2002-11-13 2004-01-20 Открытое Акционерное Общество "Фаберлик" Косметическое средство, улучшающее физиологическое состояние кожных покровов
JP4499034B2 (ja) * 2003-02-19 2010-07-07 久光製薬株式会社 Ｎ−アリール又はｎ−ヘテロアリールピペラジン誘導体及びそれを含有する医薬
JP2004352714A (ja) 2003-05-08 2004-12-16 Kyorin Pharmaceut Co Ltd 新規な４−（２−フロイル）アミノピペリジン誘導体
JP4381157B2 (ja) 2004-02-03 2009-12-09 久光製薬株式会社 ２，２−ジフェニル−１−エタノン誘導体及びそれを含有する医薬
DE602005019207D1 (de) * 2004-11-29 2010-03-18 Unilever Nv Orale zusammensetzung zur verbesserung der hauteigenschaften
KR101324539B1 (ko) * 2005-03-10 2013-11-01 도레이 카부시키가이샤 다발성 경화증에 따른 가려움의 치료에 사용하는 제품
CA2609985A1 (en) * 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
RU2299724C1 (ru) * 2005-11-14 2007-05-27 Открытое Акционерное Общество "Фаберлик" Средство, улучшающее физиологическое состояние клеток кожи

Also Published As

Publication number Publication date
CN101848714A (zh) 2010-09-29
AU2008308005A1 (en) 2009-04-09
KR20100049683A (ko) 2010-05-12
ES2748274T3 (es) 2020-03-16
EP2196206A1 (en) 2010-06-16
KR101173509B1 (ko) 2012-08-14
TW200927116A (en) 2009-07-01
EP2196206B1 (en) 2019-07-17
CA2702032A1 (en) 2009-04-09
TWI453020B (zh) 2014-09-21
CA2702032C (en) 2013-04-02
CN101848714B (zh) 2014-08-20
EP2196206A4 (en) 2010-09-22
EP2196206B8 (en) 2019-11-13
BRPI0817804A8 (pt) 2017-04-18
AU2008308005B2 (en) 2012-06-07
JPWO2009044883A1 (ja) 2011-02-10
WO2009044883A1 (ja) 2009-04-09
PL2196206T3 (pl) 2020-02-28
RU2440117C1 (ru) 2012-01-20
JP5613417B2 (ja) 2014-10-22
US20100222309A1 (en) 2010-09-02
BRPI0817804A2 (pt) 2016-10-11

Similar Documents

Publication Publication Date Title
MX2010003660A (es) Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.
SI2150530T1 (sl) Substituirani sulfonamidni derivati
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
TW200728307A (en) Novel spirochromanone derivatives
IL188172A0 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
WO2008096841A1 (ja) 二量化シクロ誘導体
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
NZ594184A (en) Skin treatment
HK1202448A1 (en) Topical formulation for administering a compound
WO2009082818A8 (en) Novel c-21-keto lupane derivatives preparation and use thereof
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
WO2010086860A3 (en) Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
BRPI0514735B8 (pt) derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
MY163762A (en) Therapeutic agent for chronic renal failure
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2008133297A1 (ja) ジスキネジアの治療または予防剤
MA33619B1 (fr) Agent thérapeutique pour des troubles de l'anxiété
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
WO2012125663A3 (en) Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal